Arsenic trioxide: Its use in the treatment of acute promyelocytic leukemia

American Journal of Cancer

Volumn 5, Issue 3, 2006, Pages 183-191

  Sanz, Miguel A ^a   Lo Coco, Francesco ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; DEXAMETHASONE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MACROLIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ABDOMINAL PAIN; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DYSESTHESIA; DYSPNEA; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INSOMNIA; KIDNEY METABOLISM; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; LUNG INFILTRATE; MICROENVIRONMENT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RETINOIC ACID SYNDROME; REVIEW; SIDE EFFECT; SORE THROAT; SURVIVAL RATE; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; TORSADE DES POINTES; VOMITING; WEIGHT GAIN;

EID: 33846851758     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605030-00005     Document Type: Review

References (55)

1. Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-67
2. Warrell RP, De Th́e H, Wang Z-Y, et al. Acute promyelocytic leukemia. Med Prog 1993; 329: 177-89
3. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1991 Nov; 8: 1913-21
4. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16 (3): 463-82
5. Alcalay M, Zangrilli D, Pandolfi PP, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A 1991 Mar 1; 88 (5): 1977-81
6. de The HC, Chomienne M, Lanotte L, et al. The t(15:17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-61
7. Borrow J, Goddard AD, Sheer D, et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-80
8. Kakizuka A, Miller WH, Umeson K, et al. Chromosomal translocation t(15:17) in human acute promyelocytic leukemia fuses RAR-alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-74
9. Early E, Moore MAS, Kakizuka A, et al. Transgenic expression of PML/RAR-alpha impairs myelopoiesis. Proc Natl Acad Sci U S A 1996; 93: 7900-4
10. Jing Y. The PML-RAR-alpha fusion protein and targeted therapy for acute promyelocytic leukaemia. Leuk Lymphoma 2004; 45: 639-48
11. Fenaux P, Le Deley MC, Castaigne S, et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176-81
12. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA+ chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-200
13. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014-21
14. Soignet SL, Fleischauer A, Polyak T, et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40 Suppl.: S25-9
15. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-8
16. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004 Feb 15; 103 (4): 1237-43
17. Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 2005; 56: 261-74
18. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 2002; 107: 1-17
19. Lengfelder E, Gnad U, Buchner T, et al. Treatment of relapsed acute promyelocytic leukemia. Onkologie 2003; 26: 373-9
20. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-53
21. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-53
22. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93
23. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-73
24. Mathews V, George B, Lakshmi KM, et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627-32
25. Sanz MA. Arsenic trioxide in the treatment of acute promyelocytic leukemia: a review of current evidence. Haematologica 2005; 90: 1231-5
26. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-33
27. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 2005; 12: 1-6
28. Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002 Jul 15; 62: 3893-903
29. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-8
30. Rousselot P, Labaume S, Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999; 59: 1041-8
31. Chou WC, Hawkins AL, Barrett JF, et al. Arsenic inhibition of telomerase transcription leads genetic instability. J Clin Invest 2001; 108: 1541-7
32. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-30
33. Product monograph (arsenic trioxide). Cell Therapeutics (UK) Ltd, 2002
34. World Health Organization. Summary and recommendations for further research: environmental health criteria 18: arsenic. Geneva: World Health Organization, 1981
35. US Environmental Protection Agency. Health assessment document for inorganic arsenic [EPA-600/8-83-021F]. US Environmental Protection Agency, 1984 Mar
36. Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60
37. Wang Z, Zhou J, Lu X, et al. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004; 17: 95-103
38. Sun HK, Ma L, Hu XC, et al. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992; 12: 170-1
39. Zhang P, Wang S, Hu L. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58-60
40. Hu X, Ma L, Hu N. Ailing no. 1 in treating 62 cases of acute promyelocytic leukemia [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 473-6
41. Zhang X, Yang L, Qiao Z. An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemic with intravenous arsenic trioxide or all-trans retinoic acid [in Chinese]. Zhonghua Nei Ke Za Zhi 1999; 38: 113-5
42. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752-7
43. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003; 97: 2218-24
44. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-24
45. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-34
46. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82: 224-9
47. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-60
48. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006, 134
49. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/ As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 5328-35
50. Hu J, Shen ZX, Sun GL, et al. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 1999; 70: 248-60
51. George B, Mathews V, Poonkuzhali B, et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004; 18: 1587-90
52. Wang GJ, Li W, Cui JW, et al. Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission in acute promyelocytic leukemia. [in Chinese] Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 85: 1093-6
53. Frankel SR, Eardley A, Lauwers G, et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-6
54. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with acute leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-6
55. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-71